

## It's Wholecare.

Updated: 06/2021 PARP Approved: 06/2021

Gateway Health
Prior Authorization Criteria **Daraprim (pyrimethamine)** 

All requests for Daraprim (pyrimethamine) require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

## Daraprim (pyrimethamine) Prior Authorization Criteria:

Daraprim (pyrimethamine) is not covered for the treatment or prophylaxis of malaria. Pyrimethamine is not included in the U.S. Centers for Disease Control and Prevention (CDC) recommendations for the prevention or treatment of malaria.

Coverage may be provided with a <u>diagnosis</u> of toxoplasmosis and the following criteria is met:

- Must be used in combination with leucovorin AND a sulfonamide, unless the member had an intolerance or contraindication or has had an inadequate response to a sulfonamide
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- Initial Duration of Approval:
  - o Acquired toxoplasmosis: 2 months
  - o Congenital toxoplasmosis: 12 months
- Reauthorization Criteria:
  - See initial criteria
- Reauthorization Duration of Approval:
  - o Acquired toxoplasmosis: 2 months
  - o Congenital toxoplasmosis: 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.



## It's Wholecare.

DARAPRIM (PYRIMETHAMINE) PRIOR AUTHORIZATION FORM Updated: 06/2021

PARP Approved: 06/2021

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Gateway Health<sup>SM</sup> Pharmacy Services. **FAX:** (888) 245-2049

If needed, you may call to speak to a Pharmacy Services Representative.

PHONE: (800) 392-1147 Monday through Friday 8:30am to 5:00nm

THOM	2. (600) 372-1147 Worlday t			ан to 3.00рш		
D (1 D 11	PROVIDER INF	ORMA				
Requesting Provider:				NPI:		
Provider Specialty: Office Address:				Office Contact:		
Office Address:			Office Phone: Office Fax:			
MPMDDD INDODMAY						
MEMBER INFORMATION  Member Name:  DOB:						
			: -1-4.	1	1	
Gateway ID: Member weight:pounds orkg						
REQUESTED DRUG INFORMATION  Medication: Strength:						
Frequency: Durati Is the member currently receiving requested medication? Yes No.						
				Medication Initiated:	1:0 0	
Is this medication being used for a ch	ironic or long-term condition	n for wh	ich the med	dication may be necessary for the	life of	
the patient? Yes No						
Billing Information						
This medication will be billed: at a pharmacy <b>OR</b>						
medically (if medically please provide a JCODE:						
Place of Service: Hospital Provider's office Member's home Other  Place of Service Information						
N	Place of Service	Inform				
Name:			NPI:			
Address:			Phone:			
MEDICAL HISTORY (Complete for ALL requests)						
Diagnosis: Acquired toxoplasmosis Congenital toxoplasmosis				ICD-10:		
Other:			ICD-10:			
Is this being used in combination with leucovorin and a sulfonamide?  Yes No						
If no, please explain:						
CURRENT or PREVIOUS THERAPY						
Medication Name	Strength/ Frequency I	Dates of	Therapy	Status (Discontinued & Why/	/Current)	
SUPPO	DRTING INFORMATION	or CL	INICAL R	ATIONALE		
Prescribing Provider	Signature			Date		
					·	